

A Novel Diagnostic And Therapeutic Target Within The Wnt Pathway

Tech ID: 25038 / UC Case 2013-019-0

TECHNOLOGY DESCRIPTION

UCSD researchers have identified and characterized a novel non-receptor for trimeric G proteins that works synergistically with the Wnt pathway receptors to enhance PI3K and beta Catenin signals to trigger oncogenesis. Since multiple cancers depend on aberrant enhancement of Wnt signaling to progress, this invention may be extremely significant for cancer research diagnosis and therapy.

Wnt signaling is essential for tissue homeostasis and its dysregulation causes cancer, Wnt ligands trigger signaling by activating Frizzled receptors, which belong to the G-protein coupled receptor superfamily. However, the mechanisms of G-protein activation in Wnt signaling remain controversial. The invention provides that frizzled receptors activate G proteins and trigger non-canonical Wnt signaling via the target, which contains binding and activating motifs which associate with binding to frizzled receptors, thereby linking Wnt stimulation to G protein activation. This then triggers non-canonical Wnt responses suppressing tumorigenesis but enhancing tumor cell invasiveness.

It has been shown that in colorectal cancer, the target is suppressed during adenoma to carcinoma transformation, and expressed later in metastasized tumor cells. Therefore, dysregulation of the target can impact both tumor initiation and progression to metastasis. The target has been cloned and therefore will be a useful tool for testing and or generation of novel agents.

A patent application has been filed.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,358,467	07/23/2019	2013-019

CONTACT

University of California, San Diego
Office of Innovation and
Commercialization
innovation@ucsd.edu
tel: 858.534.5815.



OTHER INFORMATION

CATEGORIZED AS

- ▶ **Medical**
 - ▶ Diagnostics
 - ▶ Disease: Cancer
 - ▶ Research Tools
 - ▶ Therapeutics

RELATED CASES

2013-019-0